These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31378670)

  • 21. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 22. Rogue stem cell clinics.
    Murray IR; Chahla J; Frank RM; Piuzzi NS; Mandelbaum BR; Dragoo JL;
    Bone Joint J; 2020 Feb; 102-B(2):148-154. PubMed ID: 32009438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Stem Cell Hard Sell: Report from a Clinic's Patient Recruitment Seminar.
    Knoepfler PS
    Stem Cells Transl Med; 2017 Jan; 6(1):14-16. PubMed ID: 28170181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients.
    Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C
    Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct-to-consumer stem cell marketing and regulatory responses.
    Sipp D
    Stem Cells Transl Med; 2013 Sep; 2(9):638-40. PubMed ID: 23934911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies.
    Turner L
    Regen Med; 2017 Sep; 12(6):705-719. PubMed ID: 28721755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adipose-derived stem cells: characterization and current application in orthopaedic tissue repair.
    Tapp H; Hanley EN; Patt JC; Gruber HE
    Exp Biol Med (Maywood); 2009 Jan; 234(1):1-9. PubMed ID: 19109553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims.
    Turner L; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Wang JC
    Stem Cell Reports; 2023 Nov; 18(11):2010-2015. PubMed ID: 37890484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional assessment of adipose stem cells for xenotransplantation using myocardial infarction immunocompetent models: comparison with bone marrow stem cells.
    Paul A; Srivastava S; Chen G; Shum-Tim D; Prakash S
    Cell Biochem Biophys; 2013 Nov; 67(2):263-73. PubMed ID: 22205499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse events related to unapproved stem cell products and other regenerative interventions: recommendations for more robust regulation of the direct-to-consumer marketplace.
    Akkas F; Turner L; Richardson E
    Regen Med; 2022 Feb; 17(2):63-68. PubMed ID: 34927455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments?
    Matthews K; Kunisetty B; Sprung K
    Stem Cells Dev; 2018 Nov; 27(21):1463-1465. PubMed ID: 30122128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem Cell Businesses and Right to Try Laws.
    Sipp D; Turner L; Rasko JEJ
    Cell Stem Cell; 2019 Sep; 25(3):304-305. PubMed ID: 31491393
    [No Abstract]   [Full Text] [Related]  

  • 34. Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years.
    Knoepfler PS
    Regen Med; 2019 Aug; 14(8):735-740. PubMed ID: 31456478
    [No Abstract]   [Full Text] [Related]  

  • 35. Bone marrow-derived versus adipose-derived stem cells in wound healing: value and route of administration.
    Aboulhoda BE; Abd El Fattah S
    Cell Tissue Res; 2018 Nov; 374(2):285-302. PubMed ID: 29987390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of human adipose-derived stem cells and bone marrow-derived stem cells in a myocardial infarction model.
    Rasmussen JG; Frøbert O; Holst-Hansen C; Kastrup J; Baandrup U; Zachar V; Fink T; Simonsen U
    Cell Transplant; 2014 Feb; 23(2):195-206. PubMed ID: 23211469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utah flouts FDA with new placental stem cell law.
    Wadman M
    Science; 2024 Apr; 384(6691):14-15. PubMed ID: 38574126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct-to-Consumer Advertising of Stem Cell Clinics: Ethical Considerations and Recommendations for the Health-Care Community.
    Pean CA; Kingery MT; Strauss E; Bosco JA; Halbrecht J
    J Bone Joint Surg Am; 2019 Oct; 101(19):e103. PubMed ID: 31577688
    [No Abstract]   [Full Text] [Related]  

  • 39. Marketing of unproven stem cell-based interventions: A call to action.
    Sipp D; Caulfield T; Kaye J; Barfoot J; Blackburn C; Chan S; De Luca M; Kent A; McCabe C; Munsie M; Sleeboom-Faulkner M; Sugarman J; van Zimmeren E; Zarzeczny A; Rasko JEJ
    Sci Transl Med; 2017 Jul; 9(397):. PubMed ID: 28679655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The unregulated commercialization of stem cell treatments: a global perspective.
    Sipp D
    Front Med; 2011 Dec; 5(4):348-55. PubMed ID: 21964637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.